ArticleArchives of rheumatology2026
Plasma Macrophage Migration Inhibitory Factor as a Biomarker of Thromboinflammatory Dysregulation in Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis.
Article in Archives of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune disorder characterized by necrotizing inflammation of small vessels. This study investigates the relationship among macrophage migration inhibitory factor (MIF), coagulation parameters, and thrombotic events in AAV. MATERIALS AND
methodsPlasma and urine samples obtained from 45 AAV patients and 16 healthy controls were analyzed. Then, the MIF levels were quantified via enzyme-linked immunosorbent assay. Afterwards the coagulation markers (prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen (FIB), fibrin degradation products (FDP), and prothrombin activity (PTA)), renal function (estimated glomerular filtration rate (eGFR)), and disease activity (Birmingham Vasculitis Activity Score (BVAS)) were assessed. Finally, the thrombotic events were radiologically confirmed.
resultsThe plasma MIF levels were significantly elevated in AAV patients when compared to healthy controls (716.35 vs. 293.26 pg/mL, P < .05). Beyond demonstrating the associations with disease severity and renal function (which had a positive correlation with BVAS (r = 0.391, P = .008) and a negative correlation with eGFR (r = -0.298, P = .047)), MIF further exhibited inverse relationships with high-density lipoprotein cholesterol (r = -0.334, P=.043). Notably, plasma MIF had significant positive correlations with multiple coagulation parameters, which included PT (r = 0.351), INR (r = 0.346), APTT (r = 0.380), FIB (r = 0.374), and FDP (r = 0.301) (all, P < .05), and a negative correlation with PTA (r = -0.346, P = .020). Complementing these findings, urinary MIF levels were inversely correlated to thrombin time (r = -0.367, P = .039), collectively reinforcing the role of MIF in thromboinflammatory dysregulation.
conclusionAlthough plasma MIF correlates with thromboinflammatory dysregulation, its predictive value for thrombosis warrants validation in larger cohorts. Cite this article as: Lv T, Li Y, Xu L, Hao J. Plasma macrophage migration inhibitory factor as a biomarker of thromboinflammatory dysregulation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Arch Rheumatol. 2026;41(2):108-116.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.